3rd Symposium for Emerging Viral Diseases

Campus Biotech, Geneva, Switzerland, 7-9 December 2022 https://www.unige.ch/emerging-virus-symposium/

Arnaud Didierlaurent :

"Why are children less affected than adults by SARS-CoV2 infection? An immunological perspective"

Main affiliation:
Center of Vaccinology Pathology and Immunology Department, Faculty of Medicine
University of Geneva

Actual Position:
Assistant Professor
Chaire de la fondation Giorgi-Cavalieri, Center of Vaccinology Pathology and Immunology Department, Faculty of Medicine, University of Geneva

Web site :
https://www.unige.ch/medecine/fr/

Arnaud Didierlaurent was trained as an engineer in Biotechnology in France. After gaining his Master's degree at the University of Washington (Steve Ziegler's lab) in 1999, Arnaud obtained his PhD in cellular immunology from the University of Lausanne in 2003 at ISREC in Jean-Pierre Kraehenbuhl lab. He further trained as postdoctoral fellow in Jürg Tschopp lab, Imperial college, London, and in Ralph Steinman's lab at the Rockefeller University in New York. Arnaud then joined the R&D department of GlaxoSmithKline in 2008 in Belgium, where he held several leading positions in vaccine research and development. He was notably in charge of the GSK Adjuvant portfolio and thus directly involved in the licensure of several adjuvanted vaccines. Before joining the University of Geneva, he was responsible for the launch of the GSK Zoster vaccine in Japan and European markets, as global medical affairs lead. With his experience in both academic and industrial settings, Arnaud has acquired a deep understanding of how vaccines are created, developed and deployed. He joined the Center of vaccinology in March 2020 to continue his work on translational vaccine research as Assistant Professor, with a specific interest in deciphering the interplay between innate immunity and pathogen/vaccine-specific adaptive response. He was recently appointed by WHO as chairman of the Technical Advisory Group who provides recommendations for the Emergency Use listing of COVID-19 vaccine candidates.